Role of antivirus therapy in treatment of hepatocellular carcinoma with chronic hepatitis B infection

Chinese-German Journal of Clinical Oncology

Volumn 4, Issue 6, 2005, Pages 330-333

  Cheng, Shuqun ^a   Ding, Guanghui ^a   Shi, Jie ^a   Guo, Weixin ^a   Zhao, Yuxiang ^a   Sheng, Li ^a   Liang, Liqiong ^a   Wu, Mengchao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antivirus therapy; Hepatitis; Hepatocellular carcinoma; Recurrence

Indexed keywords

EID: 30744433881     PISSN: 16101979     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10330-005-0407-4     Document Type: Article

References (13)

1. Chen H, Wu MC. Selection of therapies on recurrence of primary liver cancer after hepatectomy. Chin Med J, 1997, 77: 163-164.
2. Wu MC, Chen H, Shen F. Surgical treatment of primary liver cancer: report of 5524 patients. Chin J Surg (Chinese), 2001, 39: 25-28.
3. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C. Consensus statements on the prevention and management of hepatitis B and C in the Asia-Pacific region. J Gastroenterol Hepatol, 2000, 15: 825-841.
4. Leung NYW, Liaw F, Chang TT, et al. Durable HBeAg response in Chinese patients treated with Lamivuding. Hepatology, 2001, 34: 348A.
5. Malik AH, Lee WM. Chronic hepatitis B virus infection: Treatment strategis for the next millennium. Ann Intern Med, 2000, 132: 723-731.
6. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asian Hepatitis Lamivudine Study Group. Gastroenterol, 2000, 119: 172-180.
7. Pramoolsinsup C. Management of viral hepatitis B. J Gastroenterol Hepatol, 2002, 17(suppl): S125-s145.
8. 1 potently augments T-lymphocyte response of hydrocortisone-treated aged mice. Int J Immunopharmacol, 1995, 17: 821-828.
9. + cells in an in vitro thymic epithelia organ coculture model. Int J Immonopharmocol, 1999, 21: 15-26.
10. Serrate SA, Schulof RS, Leondaridis L, et al. Modulation of human nature killer cell cytotoxic activity: Lymphokine production, and interleukin 2 receptor expression by thymic hormones. J Immunol, 1987, 139: 2338-2343.
11. Bepler G. Thymosin alpha-1 as adjunct for conventional therapy of malignant tumors: A review. Cancer Invest, 1994, 12: 491-496.
12. 1 in patients with chronic hepatitis B: A randomized, controlled trial. Hepatology, 1998, 27: 1383-1387.
13. Lin ZY, Ren ZG, Xia JL, et al. Evaluation of therapeutic effects of TACE on primary liver cancer after radical resections. Chin J Tumor (Chinese), 2000, 22: 315-317.